Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematopoietic and Lymphatic System Neoplasm: early-phase trial registry
48 of 63 indexed Hematopoietic and Lymphatic System Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #222 of 28,707 conditions by registered trial count.
63 US clinical trials · 48 currently recruiting · #222 of 28,707 conditions by registered trial count
Hematopoietic and Lymphatic System Neoplasm: 63 US clinical trials tracked, 48 recruiting.
Hematopoietic and Lymphatic System Neoplasm is the subject of 63 registered US clinical trials on ClinicalTrials.gov, 48 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 20 of these trials.
Enrollment posture brief
Registry condition hematopoietic-and-lymphatic-system-neoplasm
OPEN 48 | RECR 76% | LATE 4 | EARLY 17 | RANK #222 | SPON 20
Volume-matched condition peers
Nearest open-share peer: TBI (Traumatic Brain Injury) (76% recruiting · 21 trials)
Hematopoietic and Lymphatic System Neoplasm lists 48 open slots (76% of 63 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematopoietic and Lymphatic System Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematopoietic and Lymphatic System Neoplasm is recruiting above its size-band peers.
48 of 63 indexed trials (76.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hematopoietic and Lymphatic System Neoplasm research.
Mayo Clinic accounts for 20 of 63 trials (31.7%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Hematopoietic and Lymphatic System Neoplasm enrolment sits around 60 participants.
Median target enrolment is 60 among the 63 trials that report a genuine target (sentinel values excluded). 36 of those (57.1%) plan for fewer than 100 participants.
-
Hematopoietic and Lymphatic System Neoplasm research is mostly interventional.
46 interventional and 17 observational studies make up this index (73% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
63 total, page 2 of 2
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
University of Rochester NCORP Research Base
NCT03996265
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
Children's Oncology Group
NCT03223753
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Children's Oncology Group
NCT03057054
Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation
Fred Hutchinson Cancer Center
NCT06026371
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
National Cancer Institute (NCI)
NCT06009926
Precision Performance Status Compared With ECOG Performance Status
University of Southern California
NCT07082257
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
NCT06357988
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
NCT05490771
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
National Cancer Institute (NCI)
NCT05142241
On the BRINK: PhotoBiomodulation (PBM) for Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell TRansplant (HSCT) - Implementing the Evidence & Discovering New Knowledge
City of Hope Medical Center
NCT06625619
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
NCT04320888
Food Safety Educational Training Program to Improve Food Safety Knowledge and Behaviors in Cancer Patients Receiving Treatment
Ohio State University Comprehensive Cancer Center
NCT06630442
A Study of Physical Activity in Cancer Survivors
Mayo Clinic
NCT05988892
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 13 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematopoietic and Lymphatic System Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematopoietic and Lymphatic System Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematopoietic and Lymphatic System Neoplasm page
63 registered trials, 48 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 48 Hematopoietic and Lymphatic System Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Hematopoietic and Lymphatic System Neoplasm trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematopoietic and Lymphatic System Neoplasm condition card totals 63 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.